SynthesisMolecular diagnosis & therapy2018
Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Molecular diagnosis & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · 2023Guideline
- ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Pooled it
- Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- Postmastectomy Reconstruction in Male Breast Cancer.The breast journal · 2022Pooled it
- Rare solid tumours as indicators of hereditary cancer syndromes.European journal of human genetics : EJHG · 2026Review
- Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study.Familial cancer · 2025Article
- Short Report: The Variants inJournal of clinical medicine · 2025Article
- Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Cohort profile: a nationwide study in DutchBMJ open · 2024Article
- Breast cancer prediction using different machine learning methods applying multi factors.Journal of cancer research and clinical oncology · 2023Article
- Article
- Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.Cancer medicine · 2022Article
- Analysis of the Clinical Advancements forCancers · 2022Review
- An Update on the General Features of Breast Cancer in Male Patients-A Literature Review.Diagnostics (Basel, Switzerland) · 2022Review
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
- Identification of Genetic Risk Factors for Familial Urinary Bladder Cancer: An Exome Sequencing Study.JCO precision oncology · 2021Article
- Review
- Male breast cancer: a disease distinct from female breast cancer.Breast cancer research and treatment · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored.
objectiveIn light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate.
methodsThis meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer.
resultsMeta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63-3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94-5.07) for male breast cancer, 2.88 (95% CI 2.63-3.16) for female breast cancer, 2.87 (95% CI 1.85-4.47) for early-onset breast cancer, 2.92 (95% CI 2.65-3.22) for invasive breast cancer, and 3.21 (95% CI 2.41-4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust.
conclusionCHEK2*1100delC is associated with an increased risk of both female and male breast cancer.
Indexed as
Identifiers
29909568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.